You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Speech-based biomarkers of CNS dysfunction associated with early Alzheimers disea

    SBC: KOBAK, KENNETH A            Topic: NIA

    DESCRIPTION (provided by applicant): More efficient methods to screen and monitor elderly patients in clinical practice and research are needed, but visits to clinical offices are expensive and many older patient are restricted by mobility or transportation access. The Alzheimer's Disease Cooperative Study (ADCS) is evaluating several technology platforms for remotely monitoring patient stat ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. QuitAdvisorOB: A tool for delivering smoking cessation guidance to pregnant women

    SBC: HEALTH DECISION TECHNOLOGIES, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): The long-term objective of this project is to provide a smoking-cessation intervention tool for health care providers in prenatal settings. Smoking during pregnancy is a significant public health issue. The prevalence of smoking in women of child-bearing age generally ranges between 17 and 35 percent worldwide, and is heavily influenced by maternal age, ethnici ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Automating MRI Delta T1 Methods for the Routine Assessment of Brain Tumor Burden

    SBC: IMAGING BIOMETRICS LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): Contrast enhancement on MRI (magnetic resonance imaging) provides the best currently available approach for measuring tumor response to therapy in brain and other solid tumors. Accordingly, criteria have been formulated, by international committees, to guide the assessment of tumor burden by measuring tumor diameters of contrast-enhancing tumor (eg RECIST, Macd ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. A non-invasive high-throughput sleep stage analysis system

    SBC: Pinnacle Technology, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Degeneration of sleep quality with age is a well-documented phenomenon. While much is known regarding the characterization of this decline, remarkably little of the physiology or genetic underpinnings are understood. Age-related sleep changes in rodents (mice + rats) are remarkably similar to those seen in human populations and as such these animal models are f ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Electronic Location Reporting for Individuals With Alzheimers Disease and other D

    SBC: INTELLISPEAK, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The proposed effort is aimed at the evaluation of a wireless electronic location system for reporting the location of individuals with Alzheimer's Disease and other Dementia (ADOD), who tend to wander or elope. This isa very vexing and routine problem for caregivers, and sometimes results in physical danger and emotional stress to the individuals who may ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A high-growth PR8 virus for pandemic vaccine production in ST6-Vero cells

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION (provided by applicant): A high-growth PR8 virus for pandemic vaccine production in ST6-Vero cells. In 2009, the traditional means of vaccine manufacturing for the H1N1 influenza pandemic failed to yield sufficient doses during the peak of thecrisis. A vaccine production method that can universally accommodate variant strains of virus in much shorter timelines would greaty benefit the ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Scarab Genomics has developed valuable reduced-genome strains of Escherichia coli in which multiple deletions remove from the genome much unwanted and all potentially hazardous DNA. These Clean Genome(R) strains, alongwith Scarab's gene expression technology, provide a system for producing high yields of premium-quality proteins very efficiently. In this P ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Antibacterial Molecular Coatings Pre-Fabricated for Biologic Wound Dressings

    SBC: IMBED BIOSCIENCES INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): The health care burden associated with treatment of chronic and burn wounds amounts to more than 25 billion annually in the U.S., involving 8.6 million patients. One recent advance in wound care has been the development of biologic dressings that contain animal-derived components such as collagen. Biologic dressings provide superior healing rates in burns ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Continuous Chromatography Device to Economically Purify Clinical-grade Antibodies

    SBC: Semba Biosciences Inc            Topic: NCI

    DESCRIPTION (provided by applicant): In today's biopharmaceutical pipeline, monoclonal antibodies (mAbs) are a predominant modality for a broad range of clinical indications including oncology and inflammatory diseases. Most antibody therapies have to be administered to the patients in large doses of 4-15 mg/kg, resulting in extremely high cost for patients (~ 2,000- 5,000 per dose; up to 10 ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Reactivation of human cells for novel fully human Ab platform

    SBC: NEOCLONE BIOTECHNOLOGY INTERNATIONAL            Topic: NCI

    DESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) have been developed into a highly effective class of therapeutic molecules, with global growth of 37% between 2001 and 2002. Since their discovery in 1975, mAbs have been described as magic bullets with the potential to seek out and target specific molecules and bind them with high affinity. Early treatment efforts using rodent ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government